A non-profit organisation representing the amyotrophic lateral sclerosis (ALS) community in the US is taking a digital approach to connecting patients with suitable clinic
Shares in Amylyx have cratered after the company reported a confirmatory trial of its amyotrophic lateral sclerosis (ALS) therapy Relyvrio missed all its objectives, putti
AstraZeneca has moved a step closer to EU approval of oral Factor D inhibitor danicopan in the EU, after the EMA’s human medicines committee, the CHMP, backed the drug as
An FDA advisory committee has voted by a huge margin that BrainStorm’s stem cell therapy for amyotrophic lateral sclerosis (ALS) – NurOwn – does not have enough data to su
Takeda has bolstered its neuroscience pipeline by licensing drug candidates from California biotech AcuraStem targeting PIKfyve, which is gathering attention as a drug tar
Sano Genetics has been awarded a grant from Innovate UK to explore the psychological impact on people at risk of motor neurone disease (MND) – also known as amyotrophic la
Today, pharma brand planning teams can benefit from technology platforms that aggregate data and automate analyses, helping unlock insights on the market landscape and clinical environment